Funding for this research was provided by:
University of Gothenburg
Article History
Received: 17 September 2023
Accepted: 12 January 2024
First Online: 24 January 2024
Competing interests
: B.E reports personal fees (expert panels, lectures) from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Mundipharma, Navamedic, Novo Nordisk, RLS Global, and Sanofi, all outside the submitted work. B.E is also supported by "Konung Gustav V:s och Drottning Victorias Stiftelse”. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their contribution to this manuscript.